Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Overall, the results with Keytruda are very similar to that seen ... also recently picked up approval for a rival TKI – Lenvima (lenvatinib) – in the US and Europe, and Merck’s vice ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its blockbuster immunotherapy Keytruda (pembrolizumab), with data presented ...

S.W. Chung and J.S. Kim equally contributed to this article as co-first authors. W.-M. Choi and K.M. Kim equally contributed to this article as co-corresponding authors.

NEW YORK (Reuters) – Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit ...

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity. Decrease or stabilization in metastatic lesions ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

There are concerns about Merck’s ability to successfully navigate the loss of exclusivity period for its blockbuster drug, Keytruda, and potential competition for Keytruda. With a weak fourth ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that have taken the leap off the patent cliff. Big Pharma is staring down the ...